2326428-19-5
Chemical Structure
CDK7-IN-2
- CAS No.: 2326428-19-5
- Formula:C26H39N7O3
- Molecular Weight:497.63
IUPAC Name: (S,E)-1-(4-(dimethylamino)but-2-enoyl)pyrrolidin-3-yl 4-((3-isopropyl-5-methylpyrazolo[1,5-a]pyrimidin-7-yl)amino)piperidine-1-carboxylate
InChIKey: GRDAHPJRLCTJNA-BXKJMJEDSA-N
SMILES: O=C(N1CCC(NC2=CC(C)=NC3=C(C(C)C)C=NN23)CC1)O[C@@H]4CN(C(/C=C/CN(C)C)=O)CC4
Biological Activity: CDK7-IN-2 is a potent inhibitor of CDK7. CDK7 is implicated in both temporal control of the cell cycle and transcriptional activity. CDK7 is implicated in the transcriptional initiation process by phosphorylation of Rbpl subunit of RNA Polymerase II (RNAPII). CDK7 has the potential for the research of cancer disease, in particular aggressive and hard- to-treat cancers (extracted from patent WO2019099298A1, compound 1)[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
CDK7-IN-2 | 98.93% | CDK7-IN-2 is a potent inhibitor of CDK7. CDK7 is implicated in both temporal control of the cell cycle and transcriptional activity. CDK7 is implicated in the transcriptional initiation process by phosphorylation of Rbpl subunit of RNA Polymerase II (RNAPII). CDK7 has the potential for the research of cancer disease, in particular aggressive and hard- to-treat cancers (extracted from patent WO2019099298A1, compound 1). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
Keywords
